A study released from Northeastern University looked at the use of Vancomycin for Lyme.
The drug which can only be administered
intravenously and is more toxic than most commonly used alternatives. IM therapy may be used but is perhaps very
painful. Oral vancomycin does not leave
the GI tract and is only for C. diff.
Studies are not in
agreement. Zhang found the drug to be relatively
ineffective in vitro, as have others.
The new study found that both
Rocephin and vancomycin are effective against stationary phase cells – round forms
and biofilms. Vancomycin was combined with a quinolone to sterilize a culture.
In an immune deficient mouse doxycycline did not clear disseminated but both
ceftriaxone (Rocephin) and Vancomycin were effective.
Vancomycin may be slightly
better than Rocephin but this far from clear.
Both inhibit peptidoglycan synthesis, the basis for cell walls.
In 2017, the Biophysical
Journal published a study about the impact of Vancomycin on Lyme spirochete
motility, significantly impaired. The
Peptidoglycan – cell wall material (under an outer membrane) was weakened with
low concentrations, subtherapeutic, of vancomycin which also inhibited the
formation of round forms or blebs. Wounded
spirochetes, unable to swim very far may do little harm.
The drug may prove very useful, especially with
subtherapeutic dosing, within a cocktail approach.
Vancomycin has been used for
decades in the treatment of MRSA, a feared superbug.
The drug is very nephrotoxic and
can cause irreversible kidney failure: serum concentrations and renal functions
must be watched carefully.
Although vancomycin is not
hoarded over by ID docs like daptomycin, ID doctors will be concerned about
sudden wild use of the drug.
Going back further, 1996 – A G
Barbour, an IDSA stalwart, found the following. Vancomycin eliminated Lyme in
immunodeficient mice only when given within 3 days of infection. When given at
7 days post infection the germs persisted; viable spirochetes were found in the
mouse brains.
In 1993 Barbour demonstrated that
in vitro vancomycin was an effective anti-Lyme therapy.
It has been long known that
vancomycin has anti-Lyme activity.
We need to know a lot more.
Treating Lyme falls within
the large purview of “the art of medicine.” In “the system” so called evidence-based
guidelines dictate medical practice. The guidelines dictate what the disease
looks like and how it is to be treated.
The existence of chronic Lyme
as we know it is soundly rejected. Nothing has changed.
Doctors who believe in
chronic Lyme agree on a several things:
Lyme is a tragic, underappreciated epidemic; Lyme is very difficult to
treat; Lyme has many faces, the “great imitator;” coinfections are an
unappreciated huge factor and I am sure a few other things.
Doctors collectively known as
LLMDs are a heterogenous group. They don’t
agree on how best to treat the illness(es). Doctors who treat the disease(s) realize we
still know very little as we try to improve our approaches as times moves on.
It is important not to jump
on every new therapy as “the answer” and be mindful of toxicity and First do no
harm.
I ask readers to refrain from jumping from preliminary preclinical small, limited basic science trial data and making quantum leaps to a new people therapy.
Vancomycin, unfortunately, is
not the cure.